Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
|
3 min read
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
|
2 min read
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
|
4 min read